MedTrace Logo

DMT210 Topical Gel in the Treatment of Atopic Dermatitis

NCT02949960 · Status: COMPLETED · Phase: PHASE2 · Type: INTERVENTIONAL · Enrollment: 19

Last updated 2018-04-18

No results posted yet for this study

Summary

The objective of the study is to evaluate the safety and efficacy of DMT210 Gel, 5% compared to vehicle control following 28 days of twice-daily topical application to selected target lesions in male and female patients with mild to moderate atopic dermatitis (AD).

Conditions

Interventions

DRUG

DMT210 Topical Gel

DMT210 Topical Aqueous Gel 5% applied twice daily

DRUG

Vehicle Control

Topical Vehicle Gel applied twice daily

Sponsors & Collaborators

  • Dermata Therapeutics

    lead INDUSTRY

Principal Investigators

  • Christopher Nardo, PhD · Dermata Therapeutics

Study Design

Allocation
RANDOMIZED
Purpose
TREATMENT
Masking
QUADRUPLE
Model
PARALLEL

Eligibility

Min Age
12 Years
Sex
ALL
Healthy Volunteers
No

Timeline & Regulatory

Start
2016-10-31
Primary Completion
2017-07-14
Completion
2017-07-14

Countries

  • United States

Study Locations

More Related Trials

Entities

Diseases

Read the full study record

This page highlights key information. For complete eligibility criteria, study locations, investigator contacts, and the full protocol, visit the original record on ClinicalTrials.gov.

View NCT02949960 on ClinicalTrials.gov